{'fraction_non_alphanumeric': 0.01878453038674033, 'fraction_numerical': 0.014364640883977901, 'mean_word_length': 5.291666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prolonged Remission in a Patient with Relapsed Follicular Lymphoma after a Single Course of Rituximab

Background: Rituximab monotherapy can achieve remissions of up to 80% in follicular lymphoma. As the antibody has only been on the market since 1997, long-term observations are still rare. Case Report: We report about a patient with follicular lymphoma who received a single treatment of 4 × 375 mg/m2 of the monoclonal antibody rituximab without chemotherapy and has been in complete remission (CR) for 8 years. Discussion: This remarkable response duration highlights the efficacy of rituximab monotherapy. A number of recently published studies have indicated that CR of more than 4 years after rituximab monotherapy may be a regularly occurring event. Conclusions: These patients are likely to represent a yet poorly characterized patient group that profits considerably from rituximab monotherapy.